Glimepirida Mabo (Glimepiride)

Glimepirida Mabo is indicated for the management of type 2 diabetes mellitus as part of a comprehensive treatment plan.

• As monotherapy in patients whose diet and exercise alone do not achieve glycemic control.
• In combination with metformin when additional glucose lowering is needed.
• As adjunct to other oral antidiabetic agents (e.g., DPP‑4 inhibitors) under physician guidance.
• To help achieve individualized HbA1c targets when lifestyle measures are insufficient.

The safety profile of Glimepirida Mabo includes a range of reported adverse effects, which are classified by frequency and severity.

Common

• Mild hypoglycemia (especially if meals are missed).
• Nausea or abdominal discomfort.
• Headache.
• Dizziness.
• Weight gain.

Serious

• Severe hypoglycemia requiring assistance.
• Allergic reactions such as rash, pruritus, or angioedema.
• Hepatotoxicity (elevated liver enzymes).
• Hematologic abnormalities (e.g., leukopenia, thrombocytopenia).

Before prescribing Glimepirida Mabo, clinicians should evaluate several patient‑specific factors to minimize risk.

• Assess renal and hepatic function; dose adjustment may be needed in impairment.
• Review history of cardiovascular disease, as sulfonylureas can affect cardiac ischemic preconditioning.
• Use caution in elderly patients due to increased hypoglycemia risk.
• Avoid use during pregnancy and lactation unless benefits outweigh risks.
• Monitor blood glucose regularly, especially when initiating therapy or changing dose.
• Consider potential for weight gain and adjust lifestyle counseling accordingly.

Glimepirida Mabo can interact with other medicines, influencing its glucose‑lowering effect or increasing adverse reactions.

Avoid

• Concomitant use with other sulfonylureas or insulin, which may cause additive hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride plasma levels.
• MAO‑B inhibitors (e.g., selegiline) that may potentiate hypoglycemia.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Thiazide diuretics, which can affect glucose tolerance.
• Corticosteroids or atypical antipsychotics that may increase blood glucose, requiring dose adjustments.